Furthermore, when BCL-2/BCL-XL was inhibited, the transcription and expression of integrin α5 were upregulated (78), which may be attributed to the fact that the synergistic inhibition of PI3K and integrin α5 leads to a reduced expression of the BCL-2 family downstream of integrin α5, mediating apoptosis in prostate cancer cells. The gene discussed is BCL2; the disease is prostate carcinoma.